BiotechTube
Naveris

Naveris

Natick, United States· Est.
naveris.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $14M

Overview

Naveris is a private, commercial-stage diagnostics company pioneering liquid biopsy tests for HPV-driven cancers, primarily oropharyngeal and anal squamous cell carcinomas. Its core technology, Tumor Tissue Modified Viral (TTMV)-HPV DNA detection, enables ultrasensitive monitoring of circulating viral DNA, allowing for earlier cancer detection, treatment response monitoring, and recurrence surveillance. With its lead product NavDx® already in clinical use and supported by a growing body of peer-reviewed publications, Naveris is positioned in the high-growth liquid biopsy market, targeting a clear unmet need in oncology care pathways.

OncologyHPV-associated Cancers

Technology Platform

Proprietary blood test platform for ultrasensitive detection of Tumor Tissue Modified Viral (TTMV) DNA, specifically for HPV-driven cancers.

Funding History

1
Total raised:$14M
Series A$14M

Opportunities

The rapid rise in HPV-driven oropharyngeal cancer creates a large and growing addressable market for early detection and surveillance.
The test's potential to reduce reliance on expensive and invasive scans and biopsies aligns with healthcare cost-containment goals, aiding reimbursement.
The proprietary TTMV technology provides a defensible niche against broader ctDNA competitors.

Risk Factors

Commercial success is heavily dependent on securing consistent insurance reimbursement, which is uncertain and can be a lengthy process.
Market adoption requires changing established clinical practices that rely on imaging.
The company's focus on a specific cancer subset (HPV+) creates concentration risk if clinical guidelines shift or competition emerges.

Competitive Landscape

Naveris operates in a specialized niche of the liquid biopsy market. While large players like Guardant Health and Foundation Medicine offer broad ctDNA panels, they lack a dedicated, ultrasensitive HPV-specific assay. Competition may come from other specialized liquid biopsy companies or academic labs developing HPV ctDNA tests, but Naveris's first-mover advantage and focused clinical evidence provide a competitive moat.

More companies in Diagnostics & Precision Medicine →More companies in United States →